

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 CFR 1.56, 1.97, and 1.98)				ATTORNEY DOCKET 37522-1002C1		APPLICATION NO. 09/910,461	
<div style="display: flex; align-items: center; justify-content: center;"> <div style="border: 1px solid black; border-radius: 50%; padding: 10px; margin: 10px;"> PATE ENT & TRADEMARK OFFICE SEP 06 2001 OIP/E JC144 </div> <div style="text-align: center;"> SHEET 1 OF 1 </div> </div>				APPLICANT(S) Peter D. Gluckman, et al.			
				FILING DATE July 20, 2001		GROUP 1639 1027	
US PATENT DOCUMENTS							
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)	
ML	A1	4,906,614	3/90	Giertz et al.	514/18	6/14/88	
FOREIGN PATENT DOCUMENTS							
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)		
ML	*B4	WO 93/02695	2/93	PCT	No		
ML	B5	WO 93/21216	10/93	PCT	No		
ML	*B6	AU-A-52601/86	7/86	AUSTRALIA	No		
OTHER DOCUMENTS							
† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)					
ML	*C5	Sara et al., Neurpactive Products of IGF-1 and IGF-2 Gene Expression in the CNS, <u>Molecular Biology and Physiology of Insulin-like Growth Factors</u> , pages 439-448, edited by Raizade, M.K., and LeRoith, D., Plenum Press, N.Y. 1991.					
ML	*C6	Guan et al., The effects of IGF-1 treatment after hypoxic-ischemic brain injury in adult rats, Journal of Cerebral Blood Flow and Metabolism 13:609-616 (1993).					
<div style="font-size: 2em; font-weight: bold;">RECEIVED</div> <div style="font-size: 1.2em;">SEP 12 2001</div>							
EXAMINER'S SIGNATURE B ce-s A				DATE CONSIDERED 4/9/03			
<div style="font-size: 1.2em; font-weight: bold;">TECH CENTER 1600/2900</div>							
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. <i>Include copy of this form in next communication to applicant.</i>							
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 USC 120. 37 CFR 1.98(d).							



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

SEP 12 2002

Sheet ____ of ____

Form PTO-1449 (Substitute)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket Number NRNZ-1002US4		TECH CENTER 600/2900 Application Number 09/804,536	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant Owner Gluckman, et al.			
				Filing Date 5/24/01		Group Art Unit 1639	
U.S. PATENTS							
Examiner Initial		Patent Number	Issue Date	First Named Inventor	Class	Subclass	Filing Date
ML		5,804,550	9/8/98	Bourguignon	514	3	—
U.S. PATENT PUBLICATIONS							
Examiner Initial		Patent Application Publication Number	Publication Date	Applicant			
PENDING U.S. PATENT APPLICATIONS							
Examiner Initial		Application Number	Filing Date	First Named Inventor	Petition to Expunge? Yes No		

B celsa

4/9/03

SEP 12 2002

TECH CENTER 1600/2900